COLORECTAL CANCER: PIPELINE AND MARKET TRENDS

    loading  Checking for direct PDF access through Ovid

Abstract

♦ An estimated 1,023,000 new cases of colorectal cancer are diagnosed each year worldwide; the malignancy accounts for an estimated 529,000 deaths.

♦ Although median survivals in colorectal cancer have increased significantly since 1996, from about 10-12 months to more than 20 months, the prognosis falls substantially in late-stage disease and unresectable metastatic colorectal cancer remains incurable.

♦ Table 1 lists selected recent regulatory approvals of drugs for the treatment of colorectal cancer.

♦ A wide variety of novel targeted therapeutics and cytotoxics are in development for colorectal cancer.

♦ Table 3 lists selected regulatory submissions and Phase III therapeutics in development for colorectal cancer.

♦ Table 4 lists selected Phase II therapeutics in development for colorectal cancer.

Related Topics

    loading  Loading Related Articles